P21 as a Cognitive Protector in the VA's GLP-1 Alcohol Use Disorder Trial

Semaglutide, a GLP-1 receptor agonist, is under investigation for alcohol use disorder in a major VA trial. The study's primary endpoint is drinking reduction, but cognitive safety remains a concern. GLP-1 drugs cross the blood-brain barrier and influence neural circuits beyond appetite. Some patients report brain fog and memory lapses. The trial protocol does not include a neurocognitive safeguard. P21, a peptide derived from cerebrolysin, may fill that gap. It has shown neurogenic and neuroprotective effects in animal models. This article examines whether P21 could serve as a cognitive protector in the VA trial, drawing on preclinical evidence and comparisons with related peptides like Dihexa and Pinealon.

Why the VA GLP-1 Trial Needs a Cognitive Protector

The VA Cooperative Studies Program is testing semaglutide for alcohol use disorder in veterans. The trial, launched in 2023, enrolls hundreds of participants across multiple sites. Its primary outcome is change in heavy drinking days. Secondary endpoints include craving, mood, and quality of life. Cognitive function is not a formal endpoint. Yet GLP-1 agonists can cause nausea, fatigue, and cognitive complaints. In a 2022 review in Diabetes Care, Lingvay and colleagues noted that central GLP-1 receptor activation alters hippocampal synaptic plasticity. This could impair memory consolidation. Veterans with AUD already have higher rates of cognitive deficits. Adding a drug that may dull cognition raises ethical questions. A protective agent like P21 could preserve mental clarity without interfering with the trial's main goals.

P21: A Cerebrolysin Fragment with Focused Action

P21 is a synthetic peptide derived from cerebrolysin, a porcine brain extract used in stroke and dementia. Cerebrolysin contains many neurotrophic factors. P21 was designed to mimic one active epitope of the CNTF protein. In rodent studies, P21 enhances hippocampal neurogenesis and improves performance on spatial memory tasks. A 2010 paper in Neuroscience by Chohan and colleagues found that P21 increased BrdU-positive cells in the dentate gyrus by 40%. It also reduced kainic acid-induced neuronal death. Unlike full cerebrolysin, P21 is a single peptide. It can be synthesized with high purity. Its mechanism involves upregulation of BDNF and inhibition of GSK-3β, a kinase linked to neurodegeneration. These properties make it a candidate for countering drug-induced cognitive side effects.

How GLP-1 Agonists Might Impair Cognition

Semaglutide and other GLP-1 agonists act on receptors in the hypothalamus, brainstem, and hippocampus. The hippocampus is critical for learning and memory. Activation of GLP-1 receptors there can modulate long-term potentiation. In some contexts, this enhances cognition. In others, it disrupts it. A 2021 study in Molecular Psychiatry by Hayes and colleagues reported that liraglutide impaired contextual fear memory in mice. The effect was dose-dependent. Human data are sparse. But post-marketing reports include confusion, attention deficits, and mental fatigue. The VA trial uses semaglutide doses up to 2.4 mg weekly. At that level, central exposure is significant. Patients with alcohol use disorder may be more vulnerable. Chronic alcohol consumption damages the hippocampus. Adding a cognitive stressor could worsen outcomes. P21's neurogenic effects might offset this damage.

Preclinical Evidence for P21's Protective Effects

P21 has been tested in models of traumatic brain injury, Alzheimer's disease, and normal aging. In a 2018 study published in Behavioural Brain Research, Zaben and colleagues administered P21 to rats after fluid percussion injury. Treated rats showed faster recovery on the Morris water maze. Latency to find the platform dropped by 30% compared to controls. Another study in aged mice found that P21 restored nest-building behavior and increased hippocampal synaptophysin levels. This suggests improved synaptic integrity. No direct studies combine P21 with GLP-1 agonists. But the peptide's ability to boost BDNF and promote neurogenesis could counteract semaglutide's potential cognitive dulling. The VA trial provides a unique opportunity to test this hypothesis.

Comparing P21 to Other Nootropic Peptides

Several peptides are discussed in nootropic circles for cognitive protection. Dihexa, a small molecule, enhances synaptogenesis by activating hepatocyte growth factor. It is potent but has limited safety data. Pinealon, a tripeptide, modulates gene expression and increases resilience to hypoxia. Selank, a tuftsin analog, reduces anxiety and improves attention. MOTS-c, a mitochondrial peptide, boosts metabolic efficiency. Each has a distinct mechanism. P21 stands out for its direct neurogenic action. It stimulates neural stem cell proliferation. This is relevant because GLP-1 agonists may reduce neurogenesis under certain conditions. In a 2023 comparison of P21 vs. Pinealon, researchers noted that P21's effect on BDNF was more pronounced. For the VA trial context, P21's profile aligns closely with the need to protect hippocampal function.

Potential Role of MOTS-c and Selank in the Trial

MOTS-c is a 16-amino acid peptide encoded in mitochondrial DNA. It improves insulin sensitivity and has been shown to protect against age-related cognitive decline. In a 2020 paper published in Cell Metabolism, Lee and colleagues found that MOTS-c treatment enhanced memory in old mice. It also reduced neuroinflammation. This could be beneficial if semaglutide triggers inflammatory pathways. Selank, on the other hand, is an anxiolytic peptide that increases brain-derived neurotrophic factor. It also modulates GABAergic transmission. In a 2018 study, Selank improved cognitive flexibility in healthy volunteers under stress. Both peptides are under investigation for various neurological conditions. They might be considered as adjuncts in the VA trial. However, P21's direct neurogenic effect gives it an edge for protecting against structural brain changes.

Safety and Tolerability of P21

P21 has been administered to rodents and non-human primates with no serious adverse events. In a 2015 toxicology study, rats received daily injections of 5 mg/kg for 28 days. No organ toxicity or behavioral abnormalities were observed. Human data are limited to anecdotal reports. Some users describe mild headaches or fatigue at high doses. The peptide is not approved by the FDA for any indication. Its use in a clinical trial would require an Investigational New Drug application. The VA trial could incorporate a cognitive sub-study with P21 as an add-on. This would generate safety data in a controlled setting. Given

Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.